Versor Investments LP Acquires Shares of 34,429 Hims & Hers Health, Inc. (NYSE:HIMS)

Versor Investments LP acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 34,429 shares of the company's stock, valued at approximately $634,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC grew its position in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Hims & Hers Health by 3.0% during the 2nd quarter. Arizona State Retirement System now owns 40,344 shares of the company's stock worth $815,000 after purchasing an additional 1,173 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Hims & Hers Health by 6.6% in the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock worth $393,000 after purchasing an additional 1,212 shares during the period. Nisa Investment Advisors LLC raised its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Finally, Swiss National Bank lifted its position in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company's stock worth $4,355,000 after purchasing an additional 2,000 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,609 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total value of $169,491.40. Following the transaction, the chief financial officer now directly owns 181,469 shares in the company, valued at $2,649,447.40. The trade was a 6.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiane Pendarvis sold 7,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the sale, the director now owns 23,917 shares of the company's stock, valued at approximately $362,342.55. The trade was a 22.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 997,433 shares of company stock worth $20,263,808 over the last quarter. Insiders own 17.71% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on HIMS. Truist Financial upped their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a "hold" rating in a research note on Thursday, July 18th. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Bank of America downgraded Hims & Hers Health from a "buy" rating to an "underperform" rating in a research note on Thursday. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a "buy" rating and a $24.00 price objective for the company. Finally, Piper Sandler reiterated a "neutral" rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $21.21.

Hims & Hers Health Stock Down 24.5 %

HIMS traded down $6.76 during midday trading on Thursday, hitting $20.85. The company had a trading volume of 62,625,345 shares, compared to its average volume of 9,152,479. The stock's 50 day moving average price is $19.51 and its 200 day moving average price is $18.77. The company has a market capitalization of $4.48 billion, a price-to-earnings ratio of 49.34 and a beta of 1.06. Hims & Hers Health, Inc. has a 52 week low of $7.40 and a 52 week high of $30.44.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. The company's quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) earnings per share. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.